Closed Loop Medicine

Activities: Training & Education Regulatory

Trending Articles

  1. Accelerating technology transfer in biopharmaceutical manufacturing This article explores how structured, digitally enabled and integrated technology transfer frameworks are accelerating the commercialisation of complex biopharmaceutical...
  2. Lonza to expand bioscience testing offering with the acquisition of Redberry Acquisition to include Red One solid-phase cytometry platform for rapid sterility and bioburden testing, which expands Lonza’s portfolio of automated, scalable solutions for...
  3. Mobile modular cleanrooms and biocontainment labs by Monmouth Scientific and IMeBIO Monmouth Scientific is proud to announce a strategic partnership with IMeBIO, a global leader in modular and mobile containment solutions
  4. Piramal Pharma Solutions formalises partnership with IntoCell Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field
  5. Bioengineered bone marrow model successfully used in cancer research Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model in vital leukaemia research

Related Content

Dosage Forms

Closed Loop Medicine launches WeDosify, the first personalised GLP-1 dosing platform in the US

Backed by 29 studies and over 15,000 patient profiles, the platform delivers personalised dosing recommendations to reduce side effects and help clinicians keep patients on therapy for longer
Digital

Closed Loop Medicine appoints Paul Johnson as Non-Executive Director

Paul will work with the company to drive forward its commercialisation strategy for its portfolio of precision care solutions
Research & Development

Closed Loop Medicine & Pharmanovia's OptiZest study for precision hypertension therapeutic commences

The study will investigate the efficacy of at-home, personalised dose management with Zestril for the treatment of hypertension
Research & Development

Teva UK and Closed Loop Medicine partner to advance personalised medicine development

SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Regulatory

First-line anti-hypertensive drug and software partnership

Hypertension is the leading preventable cause of morbidity and premature death worldwide, impacting over 1 in 4 men and 1 in 5 women, and costing the NHS alone over £2.1 billion/year
Subscribe now